The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors

Jin Kyung Rho, Yun Jung Choi, Jin Kyung Lee, Baek Yeol Ryoo, Im Il Na, Sung Hyun Yang, Seung Sook Lee, Cheol Hyeon Kim, Young Do Yoo, Jae Cheol Lee

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) seems almost inevitable, even in patients with lung cancer that initially respond well to EGFR-TKIs. MET amplification was recently found to be a mechanism of escape from the anticancer effect of EGFR inhibitors. In the present study, we investigated the means whereby MET affects sensitivity to EGFR-TKIs in PC-9 cells. Gefitinib- or erlotinib-resistant sublines were established by exposing the parental PC-9 cell line to chronic, repeated treatments with these drugs. These resistant sublines showed more than 100-fold more resistance to gefitinib and erlotinib and acquired cross-resistance to other EGFR-TKIs. The T790M EGFR mutation was found by pyrosequencing, and this seemed to be the cause of drug resistance. Resistant cells also showed MET activation, although gene amplification was not detected. Furthermore, the induction of MET activity was not found to be associated with sensitivity to EGFR-TKIs. Interestingly, increased passage number without exposure to gefitinib or erlotinib caused MET activation, but this did not affect sensitivity to EGFR-TKIs. In addition, hepatocyte growth factor was found to block the ability of EGFR-TKIs to inhibit MET activation. However, sustained MET activation by hepatocyte growth factor did not modulate the cellular effects of gefitinib or erlotinib. Rather, activated MET enhanced migration and invasion abilities. Summarizing, MET activation may be acquired during cancer cell proliferation and enhances migratory and invasive abilities without affecting cellular sensitivity to EGFR-TKIs. Accordingly, the present study suggests that MET activation caused by factors other than MET gene amplification is not a suitable surrogate marker of resistance to EGFR-TKIs.

Original languageEnglish
Pages (from-to)1736-1743
Number of pages8
JournalMolecular Cancer Research
Volume7
Issue number10
DOIs
Publication statusPublished - 2009 Oct 1

Fingerprint

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Hepatocyte Growth Factor
Gene Amplification
Drug Resistance
Lung Neoplasms
Biomarkers
Cell Proliferation
Cell Line
Mutation
gefitinib
Erlotinib Hydrochloride
Pharmaceutical Preparations
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Oncology

Cite this

The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. / Rho, Jin Kyung; Choi, Yun Jung; Lee, Jin Kyung; Ryoo, Baek Yeol; Na, Im Il; Yang, Sung Hyun; Lee, Seung Sook; Kim, Cheol Hyeon; Yoo, Young Do; Lee, Jae Cheol.

In: Molecular Cancer Research, Vol. 7, No. 10, 01.10.2009, p. 1736-1743.

Research output: Contribution to journalArticle

Rho, Jin Kyung ; Choi, Yun Jung ; Lee, Jin Kyung ; Ryoo, Baek Yeol ; Na, Im Il ; Yang, Sung Hyun ; Lee, Seung Sook ; Kim, Cheol Hyeon ; Yoo, Young Do ; Lee, Jae Cheol. / The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. In: Molecular Cancer Research. 2009 ; Vol. 7, No. 10. pp. 1736-1743.
@article{1defdeed29b645b1aed3d98dde803bae,
title = "The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors",
abstract = "The development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) seems almost inevitable, even in patients with lung cancer that initially respond well to EGFR-TKIs. MET amplification was recently found to be a mechanism of escape from the anticancer effect of EGFR inhibitors. In the present study, we investigated the means whereby MET affects sensitivity to EGFR-TKIs in PC-9 cells. Gefitinib- or erlotinib-resistant sublines were established by exposing the parental PC-9 cell line to chronic, repeated treatments with these drugs. These resistant sublines showed more than 100-fold more resistance to gefitinib and erlotinib and acquired cross-resistance to other EGFR-TKIs. The T790M EGFR mutation was found by pyrosequencing, and this seemed to be the cause of drug resistance. Resistant cells also showed MET activation, although gene amplification was not detected. Furthermore, the induction of MET activity was not found to be associated with sensitivity to EGFR-TKIs. Interestingly, increased passage number without exposure to gefitinib or erlotinib caused MET activation, but this did not affect sensitivity to EGFR-TKIs. In addition, hepatocyte growth factor was found to block the ability of EGFR-TKIs to inhibit MET activation. However, sustained MET activation by hepatocyte growth factor did not modulate the cellular effects of gefitinib or erlotinib. Rather, activated MET enhanced migration and invasion abilities. Summarizing, MET activation may be acquired during cancer cell proliferation and enhances migratory and invasive abilities without affecting cellular sensitivity to EGFR-TKIs. Accordingly, the present study suggests that MET activation caused by factors other than MET gene amplification is not a suitable surrogate marker of resistance to EGFR-TKIs.",
author = "Rho, {Jin Kyung} and Choi, {Yun Jung} and Lee, {Jin Kyung} and Ryoo, {Baek Yeol} and Na, {Im Il} and Yang, {Sung Hyun} and Lee, {Seung Sook} and Kim, {Cheol Hyeon} and Yoo, {Young Do} and Lee, {Jae Cheol}",
year = "2009",
month = "10",
day = "1",
doi = "10.1158/1541-7786.MCR-08-0504",
language = "English",
volume = "7",
pages = "1736--1743",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors

AU - Rho, Jin Kyung

AU - Choi, Yun Jung

AU - Lee, Jin Kyung

AU - Ryoo, Baek Yeol

AU - Na, Im Il

AU - Yang, Sung Hyun

AU - Lee, Seung Sook

AU - Kim, Cheol Hyeon

AU - Yoo, Young Do

AU - Lee, Jae Cheol

PY - 2009/10/1

Y1 - 2009/10/1

N2 - The development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) seems almost inevitable, even in patients with lung cancer that initially respond well to EGFR-TKIs. MET amplification was recently found to be a mechanism of escape from the anticancer effect of EGFR inhibitors. In the present study, we investigated the means whereby MET affects sensitivity to EGFR-TKIs in PC-9 cells. Gefitinib- or erlotinib-resistant sublines were established by exposing the parental PC-9 cell line to chronic, repeated treatments with these drugs. These resistant sublines showed more than 100-fold more resistance to gefitinib and erlotinib and acquired cross-resistance to other EGFR-TKIs. The T790M EGFR mutation was found by pyrosequencing, and this seemed to be the cause of drug resistance. Resistant cells also showed MET activation, although gene amplification was not detected. Furthermore, the induction of MET activity was not found to be associated with sensitivity to EGFR-TKIs. Interestingly, increased passage number without exposure to gefitinib or erlotinib caused MET activation, but this did not affect sensitivity to EGFR-TKIs. In addition, hepatocyte growth factor was found to block the ability of EGFR-TKIs to inhibit MET activation. However, sustained MET activation by hepatocyte growth factor did not modulate the cellular effects of gefitinib or erlotinib. Rather, activated MET enhanced migration and invasion abilities. Summarizing, MET activation may be acquired during cancer cell proliferation and enhances migratory and invasive abilities without affecting cellular sensitivity to EGFR-TKIs. Accordingly, the present study suggests that MET activation caused by factors other than MET gene amplification is not a suitable surrogate marker of resistance to EGFR-TKIs.

AB - The development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) seems almost inevitable, even in patients with lung cancer that initially respond well to EGFR-TKIs. MET amplification was recently found to be a mechanism of escape from the anticancer effect of EGFR inhibitors. In the present study, we investigated the means whereby MET affects sensitivity to EGFR-TKIs in PC-9 cells. Gefitinib- or erlotinib-resistant sublines were established by exposing the parental PC-9 cell line to chronic, repeated treatments with these drugs. These resistant sublines showed more than 100-fold more resistance to gefitinib and erlotinib and acquired cross-resistance to other EGFR-TKIs. The T790M EGFR mutation was found by pyrosequencing, and this seemed to be the cause of drug resistance. Resistant cells also showed MET activation, although gene amplification was not detected. Furthermore, the induction of MET activity was not found to be associated with sensitivity to EGFR-TKIs. Interestingly, increased passage number without exposure to gefitinib or erlotinib caused MET activation, but this did not affect sensitivity to EGFR-TKIs. In addition, hepatocyte growth factor was found to block the ability of EGFR-TKIs to inhibit MET activation. However, sustained MET activation by hepatocyte growth factor did not modulate the cellular effects of gefitinib or erlotinib. Rather, activated MET enhanced migration and invasion abilities. Summarizing, MET activation may be acquired during cancer cell proliferation and enhances migratory and invasive abilities without affecting cellular sensitivity to EGFR-TKIs. Accordingly, the present study suggests that MET activation caused by factors other than MET gene amplification is not a suitable surrogate marker of resistance to EGFR-TKIs.

UR - http://www.scopus.com/inward/record.url?scp=72449198117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449198117&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-08-0504

DO - 10.1158/1541-7786.MCR-08-0504

M3 - Article

VL - 7

SP - 1736

EP - 1743

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 10

ER -